| Authors: |
Singh D; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; Medicines Evaluation Unit, an IQVIA Business, Manchester, UK., Poggesi I; Clinical Pharmacology, Modeling and Simulation, GSK, Verona, Italy., Weng S; Respiratory Biostatistics, GSK, Stevenage, UK., Slade D; Respiratory Clinical Research Unit, GSK, Collegeville, PA, USA., Clow L; Respiratory, Immunology & Inflammation Research Unit (RIIRU) Medicine Development Leaders, GSK, Stevenage, UK., Patterson A; Clinical Imaging, Clinical Pharmacology and Quantitative Medicine, GSK, Stevenage, UK., McKenzie L; Quotient Sciences, Nottingham, UK., Brickhill B; Quotient Sciences, Nottingham, UK., Roe C; Quotient Sciences, Nottingham, UK., Ibrahimov E; Global Clinical Operations, GSK, Mississauga, ON, Canada., van der Palen J; Department of Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands; Section Cognition, Data and Education, Faculty of Behavioural, Management and Social Sciences, University of Twente, Enschede, the Netherlands., Donald A; Development Biostatistics, GSK, Collegeville, PA, USA., Plank M; Global Medical Affairs, General Medicines, GSK, Gold Coast, Australia. Electronic address: maximilian.x.plank@gsk.com. |
